Updates are available Correction dated 2024-03-28

Article History

Accepted: 5 October 2023

First Online: 9 November 2023

Change Date: 28 March 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41584-024-01111-x

Competing interests

: R.A. served as a consultant for Kezar, Csl Behring, AstraZeneca, Octapharma, BMS, Pfizer, Janssen, Mallinckrodt, Alexion, Q32, argenx, Boehringer-Ingelheim, Corbus and EMD-Serono, and received research funding from Pfizer, BMS, Genentech, Kezar, Csl Behring and Mallinckrodt; L.C. has received funding from Boerhinger Ingelheim, served on an advisory board for Eicos Sciences and Mitsubishi Tanabe, and has received consulting fees from Kyverna, Jasper and Genentech; P.M.M. has received consulting/speaker’s fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, outside the submitted work; R.A.V. has received a research grant from Pfizer; H.C. has received research grants, travel grants, consultancy or speaker honoraria from AbbVie, Amgen, BMS, Biogen, Janssen, Lilly, Novartis and UCB; V.P.W. served as a consultant for Kezar, CSL Behring, AstraZeneca, Octapharma, Pfizer, Janssen, Neovacs and Idera, and has received research funding from Pfizer, CSL Behring and Corbus; L.A.O. has received consulting/speaker’s fees from AbbVie, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Pfizer and Roche, outside the submitted work; J.P.C. owns stock in trust accounts in the following companies: AbbVie, Abbott Laboratories, Amgen, Allergan, Celgene, 3 M, Merck, Johnson and Johnson, Procter and Gamble, Pfizer, Gilead, Walgreens and CVS, and has served on a Safety Monitoring committee for Principia Biopharma and as an adjudicator for study entry for EMD Serono and Biogen; C.C.-S. has served as a consultant for AbbVie, Gilead, Octapharma, Pfizer and Regeneron-Sanofi and has received research funding from AbbVie, Bristol-Myers Squibb, Octapharma and Pfizer; B.F.C. has served as a consultant for Biogen Inc., Bristol Meyers Squibb, Horizon Therapeutics and EMD Serono, has received research funding from Daavlin Company, and is an investigator for Pfizer Inc and Biogen Inc; P.F.D. works for UpToDate, serves on an FDA Advisory committee, has received research grants in the past 3 years from Genentech and Bristol Myers, and was on an unpaid advisory group for Boehringer Ingelheim; L.P.D. has received speaker honoraria from Boehringer Ingelheim and has served on a data safety monitoring board for Corbus Pharmaceuticals; M.M.D. serves or has recently served as a consultant for Abcuro, Amazentis, argenx, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, MDA, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma and UpToDate, and has received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma/RaPharma and Viromed/Healixmith; F.E. has received research support and funding from Genentech and Octapharma; D.F. has received honoraria from Bristol-Meyers Squibb, Kyverna, Janssen, Amgen, UCB, Priovant and Merck, funding for contracted research from Pfizer and a research grant from Serono; Z.G. has received speaker honoraria from AbbVie, Eli Lilly, Novartis and Roche, and has served on an advisory board for Octapharma. A.J.vdK. has served on an advisory board for argenx; M.K. has received research grants, travel grants, consultancy or speaker honoraria from AbbVie, argenx, Astellas, Boehringer Ingelheim, Chugai, Corbus, Horizon Therapeutics, Kissei, Medical & Biological Laboratories, Mochida, Ono and Mitsubishi Tanabe; I.E.L. has received consulting fees from Corbus Pharmaceuticals Inc and research grants from Astra Zeneca, has served on the advisory board for Bristol-Myers Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, argenx, Octapharma, Kezaar, Orphazyme, Pfizer and Janssen, and has stock shares in Roche and Novartis; C.A.M. has served a consultant for Boerhinger Ingelheim and for the National Vaccine Injury Compensation Program; J.J.P. has received consultant fees from Alexion, Riovant, argenx, EMD-Serono, Pfizer, Kezar and Guidepoint, and clinical trial research support from Alexion, Pfizer and Kezar; J.R. has received departmental research support from the Dutch Prinses Beatrix Spierfonds, Dutch ALS foundation, Marigold foundation, Prothya Biosolutions, argenx and Health-Holland/Dutch Ministry of Economic Affairs; L.G.R. has served as an unpaid consultant for AstraZeneca, CSL Behring, Alexion, Boehringer Ingelheim, Argenx, Pfizer and Horizon Therapeutics, and has received research funding from BMS, Hope Pharmaceuticals and Lilly; J.V. has received research grants, consultancy or speaker honoraria from AbbVie, argenx, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, Horizon, Kezar, MSD, Octapharma, Pfizer, Takeda, UCB and Werfen; M.d.V. has served as a consultant for Novartis and Dynacure; M.D. has received honoraria and consultation fees from Abcuro, Biogen, CSL-Behring, Roche and Sanofi-Genzyme.

Free to read: This content has been made available to all.